🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07762118
Recruiting Not applicable

Brain Stimulation Paired With Structured Language Learning in Adults

NCT07762118 · tracked via the Priya Life Science USA tracker
Sponsor
General Neuro Inc.
Phase
Not applicable
Started
2026-09-01
Last updated
2026-08-13

Condition(s) studied

Language DevelopmentLearning

Investigational drug(s) / intervention(s)

Active transcranial electrical stimulation (tES)Sham transcranial electrical stimulation (tES)

Active transcranial electrical stimulation (tES): Non-invasive transcranial electrical stimulation delivered by a scalp-mounted headset within the LOTES-2023 limited-output envelope, paired with structured language-learning content. Adult declared range 0 to 4 mA average absolute current, maximum current density 2 mA/cm2 at the electrode contact area, and maximum session duration 60 minutes subject to a 6000 mC per-session total charge limit. Electrodes are placed in standard cephalic or extracephalic montages targeting the left perisylvian region and adjacent association cortex.

Sham transcranial electrical stimulation (tES): Sham stimulation delivered by the same scalp-mounted headset, providing the initial cutaneous sensory experience of stimulation onset without sustained current delivery, paired with the same structured language-learning content. The specific validated sham approach is selected per cohort and documented in the corresponding cohort plan.

Study summary

This study investigates whether transcranial electrical stimulation (tES) delivered during structured language-learning sessions affects the rate and quality of second-language acquisition in adults.

Adults who are learning or planning to learn a new language are randomly assigned in equal numbers to receive either active stimulation or sham (placebo) stimulation while completing structured language-learning content. Participants wear a non-invasive transcranial electrical stimulation headset that delivers a low-level electrical current through electrodes resting on the scalp, targeting cortical regions associated with language. Sessions typically last 20 to 30 minutes and may be completed at home or in person at a participating language program.

Language proficiency is measured with a standardized assessment before and after the intervention period, with additional app-derived performance metrics and participant-reported measures collected throughout. A follow-up assessment may be conducted up to 12 months after the intervention ends to evaluate whether any observed effects persist.

In this study the device is applied as a learning aid in healthy adults. It is not used to diagnose, treat, cure, or prevent any disease.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: * Adults aged 18 years or older * Able to understand the consent materials and the informed consent process in English, or in another language for which an IRB-approved consent form is available * Willing and able to participate in structured language-learning activities for the duration of the intervention period * Able to provide written informed consent Exclusion Criteria: * History of epilepsy or any seizure disorder * Active skin disease, open wounds, or significant skin irritation at electrode contact sites * Implanted electronic medical devices where stimulation would be contraindicated per device manufacturer guidance or investigator judgment after individual risk assessment * Significant cognitive impairment that would interfere with informed consent or study participation * Any other condition that, in the investigator's judgment, would compromise participant safety or the integrity of the study data

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
General Neuro, Inc. Boston Massachusetts Recruiting

More General Neuro Inc. trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07762118 on ClinicalTrials.gov ↗ ← All trials in the USA